Contact:
4008465777
×
Tonghua Dongbao's Insulin Aspart, as part of basal-bolus therapy, approved for sale in China
Date：2021-10-21
Author：东(dong)宝
Views：4
Tonghua Dongbao's Insulin Aspart Injection (tradename: Ruisulin) was approved for sale in China the other day, adding another member to the Company's insulin analog family since the launch of Insulin Glargine in 2019. This basal-bolus insulin therapy will enrich the choices for patients with diabetes, and sharpen the Company's competitive edge and consolidate its lead in the field of diabetes treatment in China.
